Shield Therapeutics plc (FRA:1JS)

Market Cap	61.78M -36.3%
Revenue (ttm)	51.31M +41.3%
Net Income	-9.08M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0470
Previous Close	0.0470
Day's Range	0.0470 - 0.0470
52-Week Range	0.0340 - 0.1470
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 16, 2026

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

• Industry: Pharmaceutical Preparations
• Founded: 2008
• Employees: 61
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1JS

Financial Performance

In 2025, Shield Therapeutics's revenue was $49.70 million, an increase of 54.45% compared to the previous year's $32.18 million. Losses were -$17.66 million, -35.05% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error